Regulation of Aryl Hydrocarbon Receptor Function by Selective Estrogen Receptor Modulators
Tóm tắt
Selective estrogen receptor modulators (SERMs), such as tamoxifen (TAM), have been used extensively for the treatment and prevention of breast cancer and other pathologies associated with aberrant estrogen receptor (ER) signaling. These compounds exhibit cell-selective agonist/antagonist activities as a consequence of their ability to induce different conformational changes in ER, thereby enabling it to recruit functionally distinct transcriptional coregulators. However, the observation that SERMs can also regulate aspects of calcium signaling and apoptosis in an ER-independent manner in some systems suggests that some of the activity of drugs within this class may also arise as a consequence of their ability to interact with targets other than ER. In this study, we demonstrate that 4-hydroxy-TAM (4OHT), an active metabolite of TAM, directly binds to and modulates the transcriptional activity of the aryl hydrocarbon receptor (AHR). Of specific interest was the observation, that in the absence of ER, 4OHT can induce the expression of AHR target genes involved in estradiol metabolism, cellular proliferation, and metastasis in cellular models of breast cancer. The potential role for AHR in SERM pharmacology was further underscored by the ability of 4OHT to suppress osteoclast differentiation in vitro in part through AHR. Cumulatively, these findings provide evidence that it is necessary to reevaluate the relative roles of ER and AHR in manifesting the pharmacological actions and therapeutic efficacy of TAM and other SERMs.
Từ khóa
Tài liệu tham khảo
Hall, 1999, The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens., Endocrinology, 140, 5566, 10.1210/endo.140.12.7179
Howell, 2001, Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?, J Steroid Biochem Mol Biol, 79, 227, 10.1016/S0960-0760(01)00140-6
Vogel, 2009, The NSABP study of tamoxifen and raloxifene (STAR) trial., Expert Rev Anticancer Ther, 9, 51, 10.1586/14737140.9.1.51
Smith, 2004, Coregulator function: a key to understanding tissue specificity of selective receptor modulators., Endocr Rev, 25, 45, 10.1210/er.2003-0023
Norris, 1999, Peptide antagonists of the human estrogen receptor., Science, 285, 744, 10.1126/science.285.5428.744
Shang, 2000, Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription., Cell, 103, 843, 10.1016/S0092-8674(00)00188-4
Gundimeda, 1996, Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells., J Biol Chem, 271, 13504, 10.1074/jbc.271.23.13504
Lopes, 1990, Ca2(+)-dependent binding of tamoxifen to calmodulin isolated from bovine brain., Cancer Res, 50, 2753
Eisen, 2002, Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells., Mol Pharmacol, 62, 911, 10.1124/mol.62.4.911
Coward, 2001, 4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor γ., Proc Natl Acad Sci USA, 98, 8880, 10.1073/pnas.151244398
Frasor, 2004, Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells., Cancer Res, 64, 1522, 10.1158/0008-5472.CAN-03-3326
Glidewell-Kenney, 2005, ERE-independent ERα target genes differentially expressed in human breast tumors., Mol Cell Endocrinol, 245, 53, 10.1016/j.mce.2005.10.003
Itoh, 2005, Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach., Mol Cancer Res, 3, 203, 10.1158/1541-7786.MCR-04-0122
Montano, 1997, The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens., Proc Natl Acad Sci USA, 94, 2581, 10.1073/pnas.94.6.2581
Denison, 1988, Inducible, receptor-dependent protein-DNA interactions at a dioxin-responsive transcriptional enhancer., Proc Natl Acad Sci USA, 85, 2528, 10.1073/pnas.85.8.2528
Klinge, 2000, The aryl hydrocarbon receptor interacts with estrogen receptor α and orphan receptors COUP-TFI and ERRα1., Arch Biochem Biophys, 373, 163, 10.1006/abbi.1999.1552
Wormke, 2003, The aryl hydrocarbon receptor mediates degradation of estrogen receptor α through activation of proteasomes., Mol Cell Biol, 23, 1843, 10.1128/MCB.23.6.1843-1855.2003
Hockings, 2006, The ligand status of the aromatic hydrocarbon receptor modulates transcriptional activation of BRCA-1 promoter by estrogen., Cancer Res, 66, 2224, 10.1158/0008-5472.CAN-05-1619
Khan, 2006, Molecular mechanism of inhibitory aryl hydrocarbon receptor-estrogen receptor/Sp1 cross talk in breast cancer cells., Mol Endocrinol, 20, 2199, 10.1210/me.2006-0100
Tsuchiya, 2004, Human CYP1B1 is regulated by estradiol via estrogen receptor., Cancer Res, 64, 3119, 10.1158/0008-5472.CAN-04-0166
MacCallum, 2000, Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours., Br J Cancer, 82, 1629
Stearns, 2003, Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine., J Natl Cancer Inst, 95, 1758, 10.1093/jnci/djg108
Cho, 2004, Disruption of cell-cell contact maximally but transiently activates AhR-mediated transcription in 10T1/2 fibroblasts., Toxicol Appl Pharmacol, 199, 220, 10.1016/j.taap.2003.12.025
Ikuta, 2004, Cell density regulates intracellular localization of aryl hydrocarbon receptor., J Biol Chem, 279, 19209, 10.1074/jbc.M310492200
Sindhu, 1996, Induction of cytochrome P4501A1 by photooxidized tryptophan in Hepa lclc7 cells., Biochem Pharmacol, 52, 1883, 10.1016/S0006-2952(97)81491-8
Ma, 2000, 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced degradation of aryl hydrocarbon receptor (AhR) by the ubiquitin-proteasome pathway. Role of the transcription activaton and DNA binding of AhR., J Biol Chem, 275, 8432, 10.1074/jbc.275.12.8432
Lu, 1995, Identification of 3′-methoxy-4′-nitroflavone as a pure aryl hydrocarbon (Ah) receptor antagonist and evidence for more than one form of the nuclear Ah receptor in MCF-7 human breast cancer cells., Arch Biochem Biophys, 316, 470, 10.1006/abbi.1995.1062
Blank, 1987, α-Naphthoflavone antagonism of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced murine lymphocyte ethoxyresorufin-O-deethylase activity and immunosuppression., Mol Pharmacol, 32, 169
Merchant, 1990, The mechanism of action of α-naphthoflavone as an inhibitor of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced CYP1A1 gene expression., Arch Biochem Biophys, 281, 84, 10.1016/0003-9861(90)90416-V
Swanson, 2002, DNA binding and protein interactions of the AHR/ARNT heterodimer that facilitate gene activation., Chem Biol Interact, 141, 63, 10.1016/S0009-2797(02)00066-2
Denison, 2003, Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals., Annu Rev Pharmacol Toxicol, 43, 309, 10.1146/annurev.pharmtox.43.100901.135828
Fukuda, 2007, Interaction between the aryl hydrocarbon receptor and its antagonists, flavonoids., Biochem Biophys Res Commun, 359, 822, 10.1016/j.bbrc.2007.05.199
Gradelet, 1997, Ah receptor-dependent CYP1A induction by two carotenoids, canthaxanthin and β-apo-8′-carotenal, with no affinity for the TCDD binding site., Biochem Pharmacol, 54, 307, 10.1016/S0006-2952(97)00176-7
Johnson, 2004, Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen., Breast Cancer Res Treat, 85, 151, 10.1023/B:BREA.0000025406.31193.e8
Lien, 1988, Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile., Cancer Res, 48, 2304
Lim, 2005, Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen., Cancer Chemother Pharmacol, 55, 471, 10.1007/s00280-004-0926-7
Furr, 1984, The pharmacology and clinical uses of tamoxifen., Pharmacol Ther, 25, 127, 10.1016/0163-7258(84)90043-3
Wu, 2009, The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor α for degradation in breast cancer cells., Cancer Res, 69, 1722, 10.1158/0008-5472.CAN-08-3933
Borges, 2006, Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment., Clin Pharmacol Ther, 80, 61, 10.1016/j.clpt.2006.03.013
Meyers, 2001, Estrogen receptor-β potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues., J Med Chem, 44, 4230, 10.1021/jm010254a
Lund, 2005, Novel actions of estrogen receptor-β on anxiety-related behaviors., Endocrinology, 146, 797, 10.1210/en.2004-1158
Yu, 2006, Mechanism of cardioprotection following trauma-hemorrhagic shock by a selective estrogen receptor-β agonist: up-regulation of cardiac heat shock factor-1 and heat shock proteins., J Mol Cell Cardiol, 40, 185, 10.1016/j.yjmcc.2005.10.001
Lewis, 2008, Effects of estrogen receptor agonists on regulation of the inflammatory response in astrocytes from young adult and middle-aged female rats., J Neuroimmunol, 195, 47, 10.1016/j.jneuroim.2008.01.006
Ward, 1993, Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women., Bone Miner, 22, 87, 10.1016/S0169-6009(08)80220-6
Shevde, 2000, Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression., Proc Natl Acad Sci USA, 97, 7829, 10.1073/pnas.130200197
Teitelbaum, 2004, Postmenopausal osteoporosis, T cells, and immune dysfunction., Proc Natl Acad Sci USA, 101, 16711, 10.1073/pnas.0407335101
Voronov, 2005, Inhibition of osteoclast differentiation by polycyclic aryl hydrocarbons is dependent on cell density and RANKL concentration., Biochem Pharmacol, 70, 300, 10.1016/j.bcp.2005.04.028
Naruse, 2002, 3-Methylcholanthrene, which binds to the arylhydrocarbon receptor, inhibits proliferation and differentiation of osteoblasts in vitro and ossification in vivo., Endocrinology, 143, 3575, 10.1210/en.2002-220003
Ryan, 2007, Environmental toxicants may modulate osteoblast differentiation by a mechanism involving the aryl hydrocarbon receptor., J Bone Miner Res, 22, 1571, 10.1359/jbmr.070615
Hushka, 1998, Characterization of 2,3,7,8-tetrachlorodibenzofuran-dependent suppression and AH receptor pathway gene expression in the developing mouse mammary gland., Toxicol Appl Pharmacol, 152, 200, 10.1006/taap.1998.8508
Tsuchiya, 2005, Cytochrome P450-mediated metabolism of estrogens and its regulation in human., Cancer Lett, 227, 115, 10.1016/j.canlet.2004.10.007
Mooberry, 2003, New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent., Curr Opin Oncol, 15, 425, 10.1097/00001622-200311000-00004
Zahid, 2006, The greater reactivity of estradiol-3,4-quinone vs estradiol-2,3-quinone with DNA in the formation of depurinating adducts: implications for tumor-initiating activity., Chem Res Toxicol, 19, 164, 10.1021/tx050229y
Spink, 1998, Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells., Carcinogenesis, 19, 291, 10.1093/carcin/19.2.291
Robertson, 2005, Endocrine treatment options for advanced breast cancer–the role of fulvestrant., Eur J Cancer, 41, 346, 10.1016/j.ejca.2004.07.035
Chouinard, 2006, Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue., Mol Pharmacol, 69, 908, 10.1124/mol.105.015891
Erichsen, 2008, Genetic variability of aryl hydrocarbon receptor (AhR)-mediated regulation of the human UDP glucuronosyltransferase (UGT) 1A4 gene., Toxicol Appl Pharmacol, 230, 252, 10.1016/j.taap.2008.02.020
Sun, 2007, Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases., Drug Metab Dispos, 35, 2006, 10.1124/dmd.107.017145
Cheung, 2008, Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment., J Pharmacol Exp Ther, 327, 288, 10.1124/jpet.108.141242
Connor, 2006, Human response to dioxin: aryl hydrocarbon receptor (AhR) molecular structure, function, and dose-response data for enzyme induction indicate an impaired human AhR., J Toxicol Environ Health B Crit Rev, 9, 147, 10.1080/15287390500196487
Chalas, 2005, Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial., Am J Obstet Gynecol, 192, 1230, 10.1016/j.ajog.2004.12.083
Cohen, 1999, Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients., Gynecol Oncol, 72, 202, 10.1006/gyno.1998.5201
Gielen, 2008, Signaling by estrogens and tamoxifen in the human endometrium., J Steroid Biochem Mol Biol, 109, 219, 10.1016/j.jsbmb.2008.03.021
Collins, 2009, Characterization of antiestrogenic activity of the Chinese Herb, Prunella vulgaris, using in vitro and in vivo (mouse xenograft) models., Biol Reprod [Erratum (2009) 80:1306], 80, 375, 10.1095/biolreprod.107.065375
Kitajima, 2004, Histomorphometric alteration and cell-type specific modulation of arylhydrocarbon receptor and estrogen receptor expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin and 17β-estradiol in mouse experimental model of endometriosis., Reprod Toxicol, 18, 793, 10.1016/j.reprotox.2004.04.012
Heilier, 2005, Increased dioxin-like compounds in the serum of women with peritoneal endometriosis and deep endometriotic (adenomyotic) nodules., Fertil Steril, 84, 305, 10.1016/j.fertnstert.2005.04.001
Nayyar, 2007, Developmental exposure of mice to TCDD elicits a similar uterine phenotype in adult animals as observed in women with endometriosis., Reprod Toxicol, 23, 326, 10.1016/j.reprotox.2006.09.007
Niskar, 2009, Serum dioxins, polychlorinated biphenyls, and endometriosis: a case-control study in Atlanta., Chemosphere, 74, 944, 10.1016/j.chemosphere.2008.10.005
Abbott, 1999, Adverse reproductive outcomes in the transgenic Ah receptor-deficient mouse., Toxicol Appl Pharmacol, 155, 62, 10.1006/taap.1998.8601
Fernandez-Salguero, 1995, Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor., Science, 268, 722, 10.1126/science.7732381
Gonzalez, 1998, The aryl hydrocarbon receptor: studies using the AHR-null mice., Drug Metab Dispos, 26, 1194
Hall, 2000, Development of peptide antagonists that target estrogen receptor β-coactivator interactions., Mol Endocrinol, 14, 2010
Oberg, 2005, Identification of the tryptophan photoproduct 6-formylindolo[3,2-b]carbazole, in cell culture medium, as a factor that controls the background aryl hydrocarbon receptor activity., Toxicol Sci, 85, 935, 10.1093/toxsci/kfi154
DuSell, 2008, 27-Hydroxycholesterol is an endogenous selective estrogen receptor modulator., Mol Endocrinol, 22, 65, 10.1210/me.2007-0383